{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:29:02Z","timestamp":1793413742856,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL122494"],"award-info":[{"award-number":["HL122494"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL139868"],"award-info":[{"award-number":["HL139868"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL125805"],"award-info":[{"award-number":["HL125805"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL033610"],"award-info":[{"award-number":["HL033610"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2018.01.025","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T19:04:11Z","timestamp":1521140651000},"page":"85-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Coupling corticotropin-releasing-hormone and angiotensin converting enzyme 2 dampens stress responsiveness in male mice"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-4306","authenticated-orcid":false,"given":"Lei A.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette D.","family":"de Kloet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Smeltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlena M.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Hiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin B.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pioquinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Ludin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Katovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan K.","family":"Raizada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.01.025_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/da.20220","article-title":"HPA axis activity in patients with panic disorder: review and synthesis of four studies","volume":"24","author":"Abelson","year":"2007","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/frne.1994.1013","article-title":"Regulation of pituitary ACTH secretion during chronic stress","volume":"15","author":"Aguilera","year":"1994","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000126866","article-title":"Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin II","volume":"61","author":"Aguilera","year":"1995","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/frne.1993.1004","article-title":"Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age","volume":"14","author":"Antoni","year":"1993","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib5","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1210\/endo.142.9.8366","article-title":"Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation Stress","volume":"142","author":"Armando","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2007.01.037","article-title":"Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress","volume":"1142","author":"Armando","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1176\/ajp.144.7.873","article-title":"CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia","volume":"144","author":"Banki","year":"1987","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jpsychires.2010.08.014","article-title":"Children suffering from separation anxiety disorder (SAD) show increased HPA axis activity compared to healthy controls","volume":"45","author":"Brand","year":"2011","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1523\/JNEUROSCI.03-07-01355.1983","article-title":"Corticotropin-releasing factor immunoreactivity is widely distributed within the central nervous system of the rat: an immunohistochemical study","volume":"3","author":"Cummings","year":"1983","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib10","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1523\/JNEUROSCI.3806-12.2013","article-title":"Angiotensin type 1a receptors in the paraventricular nucleus of the hypothalamus protect against diet-induced obesity","volume":"33","author":"de Kloet","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.psyneuen.2015.03.008","article-title":"Adipocyte glucocorticoid receptors mediate fat-to-brain signaling","volume":"56","author":"de Kloet","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00429-014-0943-1","article-title":"Reporter mouse strain provides a novel look at angiotensin type-2 receptor distribution in the central nervous system","volume":"221","author":"de Kloet","year":"2016","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib13","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1523\/JNEUROSCI.3674-16.2017","article-title":"A\u00a0unique \u201cAngiotensin-Sensitive\u201d neuronal population coordinates neuroendocrine, cardiovascular, and behavioral responses to stress","volume":"37","author":"de Kloet","year":"2017","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/HYPERTENSIONAHA.109.140145","article-title":"Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases","volume":"55","author":"Ferreira","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpu086","article-title":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","volume":"28","author":"Furuhashi","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbr.2017.05.026","article-title":"Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1-7): role of the Mas receptor","volume":"331","author":"Kangussu","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4088\/JCP.11m07316","article-title":"The renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms","volume":"73","author":"Khoury","year":"2012","journal-title":"J.\u00a0Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib18","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1210\/en.2008-0477","article-title":"Angiotensin type 1 receptors in the subfornical organ mediate the drinking and hypothalamic-pituitary-adrenal response to systemic isoproterenol","volume":"149","author":"Krause","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib19","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1523\/JNEUROSCI.0892-11.2011","article-title":"Blood-borne angiotensin II acts in the brain to influence behavioral and endocrine responses to psychogenic stress","volume":"31","author":"Krause","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib20","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1177\/1087057111413919","article-title":"Prediction of off-target effects on angiotensin-converting enzyme 2","volume":"16","author":"Kulemina","year":"2011","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00004872-199606000-00017","article-title":"Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension","volume":"14","author":"Luque","year":"1996","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/0929866522666151013130550","article-title":"Anti-hypertensive effects of diminazene aceturate: an angiotensin- converting enzyme 2 activator in rats","volume":"23","author":"De Maria","year":"2016","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10253890.2017.1296949","article-title":"Chronic overexpression of angiotensin-(1-7) in rats reduces cardiac reactivity to acute stress and dampens anxious behavior","volume":"20","author":"Moura Santos","year":"2017","journal-title":"Stress"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib24","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1126\/science.6334362","article-title":"Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients","volume":"226","author":"Nemeroff","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archpsyc.1988.01800300075009","article-title":"Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims","volume":"45","author":"Nemeroff","year":"1988","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2826.2001.00597.x","article-title":"Efferent neural projections of angiotensin receptor (AT1) expressing neurones in the hypothalamic paraventricular nucleus of the rat","volume":"13","author":"Oldfield","year":"2001","journal-title":"J.\u00a0Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/10253890701476621","article-title":"Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results","volume":"11","author":"Pavlatou","year":"2008","journal-title":"Stress"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.113.01337","article-title":"Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology","volume":"62","author":"Qi","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.113.01337","article-title":"Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology","volume":"62","author":"Qi","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00109-015-1356-1","article-title":"Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia","volume":"94","author":"Qi","year":"2016","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.regpep.2004.12.015","article-title":"Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists","volume":"128","author":"Saavedra","year":"2005","journal-title":"Regul. Pept."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/HJH.0000000000000824","article-title":"Psychiatric comorbidities in patients with hypertension\u2013a study of registered diagnoses 2009-2013 in the total population in Stockholm County, Sweden","volume":"34","author":"Sandstrom","year":"2016","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib33","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1164\/rccm.201205-0880OC","article-title":"Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models","volume":"187","author":"Shenoy","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.physbeh.2014.03.027","article-title":"Acute hypernatremia promotes anxiolysis and attenuates stress-induced activation of the hypothalamic-pituitary-adrenal axis in male mice","volume":"136","author":"Smith","year":"2014","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/PSY.0b013e3181d2f0c8","article-title":"Salivary cortisol levels in persons with and without different anxiety disorders","volume":"72","author":"Vreeburg","year":"2010","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib36","doi-asserted-by":"crossref","first-page":"11867","DOI":"10.1074\/jbc.273.19.11867","article-title":"Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene","volume":"273","author":"Walther","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuropharm.2015.12.026","article-title":"Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors","volume":"105","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.01.025_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1152\/physiolgenomics.00029.2016","article-title":"Angiotensin type 1a receptors in the paraventricular nucleus of the hypothalamus control cardiovascular reactivity and anxiety-like behavior in male mice","volume":"48","author":"Wang","year":"2016","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11906-010-0105-7","article-title":"Angiotensin-converting enzyme 2: central regulator for cardiovascular function","volume":"12","author":"Xia","year":"2010","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.neuropharm.2018.01.025_bib40","doi-asserted-by":"crossref","first-page":"R804","DOI":"10.1152\/ajpregu.00222.2010","article-title":"ACE2\/ANG-(1-7)\/Mas pathway in the brain: the axis of good","volume":"300","author":"Xu","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081830025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081830025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T10:11:34Z","timestamp":1582539094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081830025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":40,"alternative-id":["S002839081830025X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.025","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coupling corticotropin-releasing-hormone and angiotensin converting enzyme 2 dampens stress responsiveness in male mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}